Stock Events

Stock Events

Novavax 

$8.71
1074
-$0.13-1.53% Today

Statistics

Day High
9.29
Day Low
8.65
52W High
9.92
52W Low
5.43
Volume
4,921,546
Avg. Volume
4,614,621
Mkt Cap
1.42B
P/E Ratio
3.78
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 7
$2.13
Nov 7
$2.13
Oct 7
$2.13
Sep 7
$2.13
Aug 7
$2.13
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

4MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.25
0.14
1.54
2.93
Expected EPS
-0.488579
Actual EPS
N/A

Financials

-27.49%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.36BRevenue
-375MNet Income

Analyst Ratings

$12.83Average Price Target
The highest estimate is 19.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
17%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVAX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, similar to Novavax's efforts in vaccine development.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, in collaboration with BioNTech, developed a COVID-19 vaccine that competes directly with Novavax's COVID-19 vaccine.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech partners with Pfizer for the COVID-19 vaccine, making it a direct competitor to Novavax in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson developed a single-shot COVID-19 vaccine, competing in the same pandemic response market as Novavax.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca developed a COVID-19 vaccine using a different technology but competes in the same global vaccine market as Novavax.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is working on COVID-19 vaccine candidates and influenza vaccines, positioning it as a competitor in the broader vaccine market.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, with its extensive vaccine portfolio and efforts in COVID-19 vaccine development, competes in the same space as Novavax.
CureVac N.V.
CVAC
Mkt Cap1.2B
CureVac competes in the mRNA vaccine space, focusing on COVID-19 and other diseases, similar to Novavax's approach.
Novavax
NVAX
Mkt Cap1.36B
Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.
Dynavax Technologies
DVAX
Mkt Cap1.2B
Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.

About

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. John Charles Jacobs M.B.A.
Employees
952
Country
US
ISIN
US6700024010

Listings

VI
AT
NVAX.VI
LSE
GB
0A3S.LSE
MX
MX
NVAX.MX
F
DE
NVV1.F

0 Comments

Share your thoughts

FAQ

What is Novavax stock price today?▼
The current price of NVAX is $8.71 USD — it has decreased by -1.53% in the past 24 hours. Watch Novavax stock price performance more closely on the chart.
What is Novavax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novavax stocks are traded under the ticker NVAX.
Is Novavax stock price growing?▼
NVAX stock has fallen by -9.18% compared to the previous week, the month change is a +22.67% rise, over the last year Novavax has showed a +0.65% increase.
What is Novavax market cap?▼
Today Novavax has the market capitalization of 1.42B
When is the next Novavax earnings date?▼
Novavax is going to release the next earnings report on March 04, 2026.
What were Novavax earnings last quarter?▼
NVAX earnings for the last quarter are -1.25 USD per share, whereas the estimation was -1.2 USD resulting in a -4.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Novavax revenue for the last year?▼
Novavax revenue for the last year amounts to 1.36B USD.
What is Novavax net income for the last year?▼
NVAX net income for the last year is -375M USD.
Does Novavax pay dividends?▼
Yes, NVAX dividends are paid monthly. The last dividend per share was 2.13 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Novavax have?▼
As of February 02, 2026, the company has 952 employees.
In which sector is Novavax located?▼
Novavax operates in the Health Care sector.
When did Novavax complete a stock split?▼
The last stock split for Novavax was on May 10, 2019 with a ratio of 1:20.
Where is Novavax headquartered?▼
Novavax is headquartered in Gaithersburg, US.